Pink Hunter
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Think we have to MedFlash Obama, what is his phonenumber. Lol
I agree, dont split your brain on this.
Maybe you can buy those shares on E-Bay.lol
Power hour......or power shower???
Sleeping giant!! Maybe too much Tranquillizers.
Hi Blue, shine a light on NBRI
The TRIGGER is...................
A 30M buy order. Who has the cash????? LOL
ARCA wants them cheap.
@ Ameritrade: Opening transactions for this security are not accepted.
3 years ago IBTY was @ $$ 3.00 !!!!!!!
My G******D, what HAPPENED ????????
No R/S
I suppose,.. we have to go back UP !!
Wow........AVVW on Americanbulls home page!!!!!!!
http://www.americanbulls.com/Default.asp
*******GBDX Tomorrow!!!!!!!!!!!!!!!!!!!
The Good....The Bad.......and the Ugly.
SSSSHHHH*********TTTTT, we are the UGLY. LOL.
GCOG Give us some drilling news!
8 M Dump was a little tooo much.
They drop 11M into the news. What a dogs.
The buyout was only for the old CEO. What a flufff PR again.
That's me LOL. BRRRR take's 4 partials to sell 100k @ 0.018 still
20k to go. Hope Accumulator finished his vodka party last night.
Think Sib Almaz says: Thank You, thank you very much for your cheap shares.
The report is expected to be delivered during the fourth quarter of 2007. LOL.
Today Rick's printer is fully loaded. LOL.
Time to Squeeeeeze CINN.
they like the 4 digit game
Today's NEWS:
Amarin Corp Plc (NASDAQ CM: AMRN - http://finance.yahoo.com/q?s=amrn)
Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntington's Disease Conference Call Begins Today at 11:00 a.m. Eastern Time
Amarin Corporation plc ("Amarin" or the "Company") today announces top-line results from its two Phase III clinical trials of Miraxion to treat Huntington's disease (HD). The Company conducted two Phase III double-blind, placebo-controlled studies in which HD patients were randomized to receive either placebo or 2 grams (1 gram twice daily) of Miraxion daily for six months. Study data showed no statistically significant difference in either study between Miraxion and placebo with regard to the primary and secondary endpoints.
These top-line findings are inconsistent with earlier clinical trial data that showed statistical significance in a subset of HD patients with a CAG repeat length of less than or equal to 44.
The primary endpoint of the trials was a change in the Total Motor Score 4 (TMS-4) component of the Unified Huntington's Disease Rating Scale (UHDRS). TMS-4 has been shown to be a sensitive measure of movement disorder in patients with HD. In addition, secondary endpoints included cognition and Total Functional Capacity outcomes. Miraxion was found to be safe and well-tolerated by patients.
Commenting on today's announcement, Rick Stewart, Chief Executive Officer of Amarin, said, "We are extremely surprised and disappointed by these top-line results, and we are analyzing the data in order to better understand the full and complete data set and outcomes. We are particularly disappointed that, at this time, we are not in a position to bring any positive news to those patients who are suffering from this devastating disease and to the broader HD community." "Despite this setback with Miraxion to treat HD, we remain committed to developing Amarin's substantial central nervous system (CNS) development pipeline." commented Mr. Stewart. "We continue to evaluate the potential of Miraxion in treating CNS disorders and specifically our next steps with respect to the HD trials. We also intend to progress the development of our novel, oral formulation of apomorphine to treat the 'off' episodes in advanced Parkinson's disease patients, our recently in-licensed nasal formulation of lorazepam for the out-patient treatment of emergency seizures in epilepsy patients and our proprietary combinatorial lipid pre-clinical program in CNS disorders and other indications." concluded Mr Stewart.
Thomas Lynch, Amarin's Chairman, added "Our commitment to neurology research and product development remains steadfast and we will continue to pursue other in-licensing opportunities while we advance our broad pipeline of products to treat CNS disorders. Amarin has in place an experienced and committed management team and a strong financial position with approximately $29 million in cash at the end of March 2007." The first study, TREND-HD, was conducted in 42 sites in the U.S. and Canada by the Huntington Study Group (HSG) based at the University of Rochester Medical School in Rochester, N.Y. This study, led by Principal Investigator Prof. Ira Shoulson, enrolled 316 patients with HD. The TREND-EU Phase III study was conducted in 27 sites in six countries across Europe and was conducted in conjunction with the European HD Network. This study was led by Principal Investigator Prof. Bernhard Landwehrmeyer, and enrolled 290 patients with HD.
These trials were developed under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA) and Miraxion for HD has Fast Track designation by the FDA and Orphan Drug designation in both the U.S. and in Europe.
Conference Call
Amarin management will host a conference call to discuss the clinical results from the two Phase III trials today beginning at 11:00 a.m. Eastern time. To participate in the call, please dial (800) 968-7995 from the U.S. or (706) 679-8403 from outside the U.S. A telephone replay will be available for a limited time following completion of the call by dialing (800) 642-1687 or (706) 645-9291, and entering reservation number 7199876. Participants can access the call over the Internet by visiting www.amarincorp.com where the call will be archived there for a limited period of time.
About the Huntington Study Group
The Huntington Study Group is a non-profit group of physicians and other healthcare providers from medical centers in the U.S., Canada, Europe and Australia, experienced in the care of Huntington's disease patients and dedicated to clinical research of Huntington's disease. The HSG central operating office and Clinical Trials Coordination Center are located at the University of Rochester.
About the European HD Network
The European HD Network is a non-profit group of physicians and other healthcare providers in Europe. The European HD network's aim is to provide a platform for professionals and people affected by HD and their relatives to facilitate working together throughout Europe. The European HD Network facilitates the conduct of natural history and interventional trials.
About Amarin
Amarin is committed to improving the lives of patients suffering from diseases of the central nervous system. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.
Amarin's core development pipeline includes Miraxion for CNS disorders, an oral formulation of apomorphine for treating patients with advanced Parkinson's disease, a nasal formulation of lorazepam for treating emergency seizures and our proprietary pre-clinical combinatorial lipid program.
Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively.
For press releases and other corporate information, visit the Amarin website at www.amarincorp.com. Information on our website does not form part of this press release.
How the story ended when the tsunami was over. Bet we see $ 1,30
by friday.
Time to take some off the table too. Think the Hammer is tooooo heavy.
I bet float is now over 10M. Or are shorties That Crazy.
They R/S me with 500K @ 0.003. First I have to wait to see the 0.03.
In 2 days almost 3 times the float traded. Is there a Spare Float??
Porsche: It was another scammy day. At least WGLT tell us they gonna throw a tsunami over us.
Let's say there are 600M in the float by now, divided by conservative revenue expectations of 22M. PPS should be $ 0.03.
If Mr. dilluto put 1 B in the market we are @ $ 0.022.
2B makes $ 0.0045. 3Billion and we are @ $ 0.0007. Wow, that's where we are today. LOL.
This is RED RED Bloody RED. We have to call 911.
hmmm, yesterday's after hours fire, was a fire without smoke.LOL
Shouda, was boring and grap them @ 0.0036. Little profit is a profit isn't.
We'll see tomorrow how much they know.
JEEE, they grap my GTC 136900 after hours @0.0044.
Todays ECFL news on BusinessWire:
http://home.businesswire.com/portal/site/home/index.jsp?ndmHsc=v2*A1170680400000*C1173358800000*Dgro...
Well well, now the Longs get triggered.
This is a flippers dream.
Wait, he cant sell @ these prices. He has to take it up like last time.
This is going CRAZY. Lets see how shorties get TRIGGERED.
Come on Rick, Still waiting for your 400M shower.
But if you wanna sell @ a decent price, you first have to buy 40M to take pps up. Just like you did last time. I know that institutionals are not interested at 0.0013.